Skip to main content
Premium Trial:

Request an Annual Quote

Definiens, MolecularMD Partner to Provide Quantitative Tissue Assays for Oncology

NEW YORK (GenomeWeb) –Definiens and MolecularMD said today that they will partner to provide customized diagnostic solutions in oncology.

Definiens specializes in what it calls "tissue phenomics" for biomarker and companion diagnostics development and commercialization. MolecularMD develops custom molecular diagnostic products and supports clinical trial services for targeted cancer therapies.

Under the partnership, the companies plan to combine MolecularMD's expertise in specialty diagnostic assays with Definiens' quantitative tissue read-outs in order to provide custom solutions that meet data and regulatory requirements for both biopharmaceutical clients and academic medical center oncology programs.

"This agreement brings together MolecularMD's proven track record in clinical assay development and companion diagnostics with Definiens' unparalleled image analysis platform to provide the confidence of an integrated solution in stratifying patients," Definiens chief commercial officer Merrilyn Datta said in a statement.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.